13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • AZTEC

    Acronym: 

    AZTEC

    ACTRN/NCT /ethics: 

    NCT03464942

    Scientific title: 

    Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer

    Summary of trial and patient characteristics

    Cancer Type Breast
    Trial Type Treatment
    Phase Phase II Tumour Stream Breast
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced
    Sex Both Anticipated Start Date 2018-08-01
    Molecular Target Anticipated End Date 2022-04-01
    Cancer Type Breast
    Trial Type Treatment
    Phase Phase II
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Breast
    Cancer Stage Locally Recurrent or Locally Advanced
    Anticipated Start Date 2018-08-01
    Anticipated End Date 2022-04-01

    Trial Summary

    A randomised phase II trial comparing the efficacy of single dose or fractionated SABR (Stereotactic ablative body radiotherapy) with AteZolizumab in patients with advanced Triple nEgative breast Cancer (AZTEC)

    Lay Summary

    Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer

    Sponsor / Cooperative group

    Peter MacCallum Cancer Centre, Australia

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Royal Adelaide Hospital Anne Milton anne.milton@sa.gov.au 08 7074 2342 Recruiting